

PROFESSIONAL INFORMATION

This unregistered medicine has not been evaluated by SAHPRA for its quality, safety or intended use.

SCHEDULING STATUS: S0

1. NAME OF THE MEDICINE: CERIVA

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Serving Size About 1 tablet
Servings Per Container: 30 pack size 30

Huperzine A [from toothed clubmoss (Huperzia serrata) whole plant extract]	200 mcg
Polypeptide Complex (from colostrum)	100 mcg

Other Ingredients: Microcrystalline cellulose, croscarmellose sodium, stearic acid (vegetable), and silica.
Contains: Milk

For full list of excipients, see section 6.1

This product is non-GMO and gluten-free.

3. PHARMACEUTICAL FORM

Cream with speckles uncoated tablets

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Ceriva is formulated to support healthy cognition and memory by beneficially modulating the metabolism of the neurotransmitter acetylcholine and aiding neuroprotection. *

* This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. **Ceriva** does not intend to prevent or cure any form of illness or disease and should not replace any medication. If you suffer from a chronic medical condition, consult your healthcare practitioner before using this product.

4.2 Posology and method of administration

Take one tablet once daily with food or as directed by your healthcare practitioner. Do not exceed two tablets daily

4.3 Contraindications

Avoid use if taking acetylcholinesterase inhibitors or cholinergic medications, or if you have a seizure disorder, cardiac arrhythmia, benign prostatic hypertrophy, asthma, chronic respiratory condition, peptic ulcer, inflammatory bowel disease, or malabsorption syndrome.

4.4 Special warnings and precautions for use

For adult use only. If you have suppressed immune function or are taking medication, including blood thinning medications and immunomodulators, consult your healthcare practitioner before use.
Please keep out of the reach of children

4.5 Interaction with other medicines and other forms of interaction

Blood thinning medications
Immunomodulators
Acetylcholinesterase inhibitors
Cholinergic medications

4.6 Fertility, pregnancy and lactation

There are no adequate data from the use of **Ceriva** in pregnant or breast-feeding woman.

4.7 Effects on ability to drive and use machines

Use with caution when driving or operating machinery.

4.8 Undesirable effects

Rare but mild and temporary anxiety, mood change, sleep disturbance, dizziness, or fatigue may be experienced.

4.9 Overdose

Treatment is symptomatic and supportive.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Category of medicine: D (Complementary Medicine)
Class of medicine: 34.13 Health supplements - Other

5.2 Pharmacokinetic properties

Pharmacokinetic studies have not been conducted on **Ceriva** product

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Microcrystalline cellulose
Croscarmellose sodium
Stearic acid (vegetable)
Silica

6.2 Incompatibilities

None known.

6.3 Shelf Life

24 Months.

6.4 Special precautions for storage

Keep tightly closed in a cool, dry place.
Keep tablets in original container until required for use.
KEEP OUT OF REACH OF CHILDREN.

6.5 Nature and contents of container

Packs 30 tablets in amber glass bottles with PET lids.
Pack-size: 90 tablets

6.6 Special precautions for disposal

No special requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION

Amipro Advanced Development Products (pty) Ltd
Unit 3 Eastgate Business Park, 1 South Road, Marlboro, Sandton, Johannesburg 2063
Tel: 011 802 8101

8. REGISTRATION NUMBER

Will be allocated by SAHPRA upon registration.

9. DATE OF FIRST AUTHORISATION

Will be allocated by SAHPRA upon registration.